Through our culture of collaboration, connectivity and data-based science, MD Anderson experts have set the standard for how immunotherapy is used to treat patients with cancer across the globe. Our faculty are working to bring the benefits of immunotherapy to even more patients by integrating immunobiology across all cancer disciplines. MD Anderson’s unique environment and vast resources allow researchers to accelerate novel discoveries into practice-changing therapies that propel us closer to our goal: a world free of cancer.
At the Society for Immunotherapy of Cancer (SITC) Annual Meeting, our experts are showcasing pacesetting research and joining colleagues for discussion on the latest science, development and application of immunotherapy.
Featured News
MD Anderson experts spotlight key immunotherapy advances at 2025 SITC Annual Meeting
As immunotherapy continues to transform cancer care, researchers at MD Anderson are sharing new insights at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting about how the immune system can be trained, guided and strengthened to improve patient outcomes. MD Anderson scientists and clinicians will present nearly 30 abstracts and lectures at this year’s meeting.
Institutes at MD Anderson
United by a shared mission to end cancer, MD Anderson clinicians and scientists work seamlessly together to advance groundbreaking research that can transform the field of immunotherapy. Leveraging our unique research ecosystem, including three leading institutes, we are pioneering new prevention, diagnostic and treatment approaches to address the most pressing needs for patients with cancer.
James P. Allison Institute
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
Institute for Cell Therapy Discovery & Innovation
Building upon unparalleled expertise, MD Anderson’s Institute for Cell Therapy Discovery & Innovation is leading the world in developing and advancing impactful cell therapies for patients in need. By uniting the top minds in the field to lead exceptional fundamental, translational and clinical research, we're focused on creating breakthrough off-the-shelf therapies that can be readily adapted for both hematologic and solid tumors as well as devastating auto-immune conditions, infections and other diseases.
Learn more about the Institute for Cell Therapy Discovery & Innovation
Institute for Data Science in Oncology
The Institute for Data Science in Oncology (IDSO) integrates the tremendous power of meaningful data extraction and interpretation with MD Anderson’s unparalleled scientific and clinical expertise to transform research and care to impact patients.
Our research by the numbers
$1.3B
invested in research
1,556
clinical trials
188
patents awarded
From Sept. 1, 2023 to Aug. 31, 2024
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities from undergraduate degrees to graduate medical education opportunities.
